Cargando…
Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment
BACKGROUND: There are limited data available on the treatment and outcome of epidermal growth factor receptor (EGFR) exon 20-mutated lung cancer patients. Hence, we planned an analysis of the demographic details, clinical profile and survival of lung cancer patients with exon 20 mutations. We compar...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476719/ https://www.ncbi.nlm.nih.gov/pubmed/28652772 http://dx.doi.org/10.2147/OTT.S133245 |
_version_ | 1783244648208138240 |
---|---|
author | Noronha, Vanita Choughule, Anuradha Patil, Vijay M Joshi, Amit Kumar, Rajiv Susan Joy Philip, Deepa Banavali, Shripad Dutt, Amit Prabhash, Kumar |
author_facet | Noronha, Vanita Choughule, Anuradha Patil, Vijay M Joshi, Amit Kumar, Rajiv Susan Joy Philip, Deepa Banavali, Shripad Dutt, Amit Prabhash, Kumar |
author_sort | Noronha, Vanita |
collection | PubMed |
description | BACKGROUND: There are limited data available on the treatment and outcome of epidermal growth factor receptor (EGFR) exon 20-mutated lung cancer patients. Hence, we planned an analysis of the demographic details, clinical profile and survival of lung cancer patients with exon 20 mutations. We compared our results to patients with EGFR tyrosine kinase inhibitor (TKI)-sensitizing activating and EGFR/anaplastic lymphoma kinase (ALK)-negative mutations. METHODS: This was a retrospective analysis of lung cancer patients who were treated at our center between January 2010 and August 2014. We reviewed the results of EGFR mutation testing by real-time polymerase chain reaction and Sanger sequencing. We also reviewed the data relating to baseline demographics, clinical profile, patient treatment and outcome measures in terms of response and overall survival (OS). RESULTS: A total of 580 patients fulfilled the selection criteria. In all, 227 (39.1%) patients had EGFR TKI-sensitizing activating mutations, 20 (3.4%) patients had exon 20 insertion mutations and 333 patients were EGFR/ALK mutation negative (57.5%). The median OS was 5 months (95% confidence interval [CI] 0.17–9.8 months) in exon 20 insertion mutations, 16.1 months (95% CI 12.8–19.5 months) in EGFR TKI-sensitizing activating mutations and 10 months (95% CI 7.9–12.1 months) in EGFR/ALK mutation-negative patients. The median OS was significantly better for the EGFR TKI-sensitizing activating mutation group (P=0.000, log-rank test) and for the EGFR/ALK-negative group (P=0.037, log-rank test) compared to the exon 20-mutated group. CONCLUSION: Exon 20 mutation results in a poorer OS prognosis compared to EGFR- and ALK-negative patients and patients harboring EGFR TKI-sensitizing activating mutations. The incidence of de novo exon 20 insertions was 3.4%. Different types of exon mutations seem to have different outcomes. |
format | Online Article Text |
id | pubmed-5476719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54767192017-06-26 Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment Noronha, Vanita Choughule, Anuradha Patil, Vijay M Joshi, Amit Kumar, Rajiv Susan Joy Philip, Deepa Banavali, Shripad Dutt, Amit Prabhash, Kumar Onco Targets Ther Original Research BACKGROUND: There are limited data available on the treatment and outcome of epidermal growth factor receptor (EGFR) exon 20-mutated lung cancer patients. Hence, we planned an analysis of the demographic details, clinical profile and survival of lung cancer patients with exon 20 mutations. We compared our results to patients with EGFR tyrosine kinase inhibitor (TKI)-sensitizing activating and EGFR/anaplastic lymphoma kinase (ALK)-negative mutations. METHODS: This was a retrospective analysis of lung cancer patients who were treated at our center between January 2010 and August 2014. We reviewed the results of EGFR mutation testing by real-time polymerase chain reaction and Sanger sequencing. We also reviewed the data relating to baseline demographics, clinical profile, patient treatment and outcome measures in terms of response and overall survival (OS). RESULTS: A total of 580 patients fulfilled the selection criteria. In all, 227 (39.1%) patients had EGFR TKI-sensitizing activating mutations, 20 (3.4%) patients had exon 20 insertion mutations and 333 patients were EGFR/ALK mutation negative (57.5%). The median OS was 5 months (95% confidence interval [CI] 0.17–9.8 months) in exon 20 insertion mutations, 16.1 months (95% CI 12.8–19.5 months) in EGFR TKI-sensitizing activating mutations and 10 months (95% CI 7.9–12.1 months) in EGFR/ALK mutation-negative patients. The median OS was significantly better for the EGFR TKI-sensitizing activating mutation group (P=0.000, log-rank test) and for the EGFR/ALK-negative group (P=0.037, log-rank test) compared to the exon 20-mutated group. CONCLUSION: Exon 20 mutation results in a poorer OS prognosis compared to EGFR- and ALK-negative patients and patients harboring EGFR TKI-sensitizing activating mutations. The incidence of de novo exon 20 insertions was 3.4%. Different types of exon mutations seem to have different outcomes. Dove Medical Press 2017-06-09 /pmc/articles/PMC5476719/ /pubmed/28652772 http://dx.doi.org/10.2147/OTT.S133245 Text en © 2017 Noronha et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Noronha, Vanita Choughule, Anuradha Patil, Vijay M Joshi, Amit Kumar, Rajiv Susan Joy Philip, Deepa Banavali, Shripad Dutt, Amit Prabhash, Kumar Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment |
title | Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment |
title_full | Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment |
title_fullStr | Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment |
title_full_unstemmed | Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment |
title_short | Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment |
title_sort | epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476719/ https://www.ncbi.nlm.nih.gov/pubmed/28652772 http://dx.doi.org/10.2147/OTT.S133245 |
work_keys_str_mv | AT noronhavanita epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment AT choughuleanuradha epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment AT patilvijaym epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment AT joshiamit epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment AT kumarrajiv epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment AT susanjoyphilipdeepa epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment AT banavalishripad epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment AT duttamit epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment AT prabhashkumar epidermalgrowthfactorreceptorexon20mutationinlungcancertypesincidenceclinicalfeaturesandimpactontreatment |